ETFs that lend portfolio securities can generate additional income, but disclosure on those activities isn't forthright
90% of the assets put in ETFs in quarter went to low-cost provider.
<i>Breakfast with Benjamin:</i> Fighting technology with technology. Plus: Know your ETF or don't invest, how not to advise clients, a pyramid to financial success, biotech on the rebound, and Russia addresses meat shortage with the Easter turkey
<i>Breakfast with Benjamin:</i> It's a bad time for stocks, based on the presidential cycle. Plus: The Nasdaq tests correction territory; most money managers think U.S. stocks are pricey (but there is a market they love); a tech ETF for nervous investors; what advisers wish investors knew; and having delicious fun with Crème Eggs.
After shutting its exchange-traded fund unit in 2002, Nuveen comes back to the table with a new plan.
<i>Breakfast with Benjamin:</i> All eyes are on earnings. Plus: The SEC discovers high-frequency trading, momentum takes out passive investors, AAA credit ratings becoming extinct, new love for emerging markets, six solid stocks to watch this week, overwhelmed at the IRS, and Switzerland votes for the world's highest minimum wage.
<i>Breakfast with Benjamin:</i> Markets wake up to China's economic slowdown. Plus: Soros deters British EU exit, an all-ETF retirement portfolio, rethinking cash-rich tech companies, undervalued Wall Street banks, and test your investor profile (for fun).
Money is flooding into exchange-traded funds focused on health care at the fastest rate in at least six years, driven by booming biotechnology and pharmaceutical sectors bringing new products to market.
ETF firm launches five funds to offer pure-play exposure to Japanese companies.
